Drug

CMK389

Status:
Phase 2
Condition:
Sarcoidosis ILD
Intervention Type:
Intravenous (IV) Injection
Funder Type:
Industry

Drug Details

CMK389 is an IL-18 Inhibitor.

Study Purpose

The purpose of this proof of concept study is to determine whether CMK389 displays the safety and efficacy profile to support further development in chronic pulmonary sarcoidosis.

Find a Clinical Trial